Keyphrases
Japan
75%
Relapsed or Refractory
71%
Overall Survival
70%
Diffuse Large B-cell Lymphoma (DLBCL)
62%
Peripheral T-cell Lymphoma
54%
Follicular Lymphoma
53%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
52%
Lymphoma
49%
Mantle Cell Lymphoma
43%
Rituximab
43%
Non-Hodgkin Lymphoma
34%
Hairy Cell Leukemia
33%
Adult T-cell Leukemia
33%
Confidence Interval
33%
Progression-free Survival
32%
Lymphoma Patients
31%
Chimeric Antigen Receptor T-cell Therapy
31%
T-cell Lymphoma
30%
Marginal Zone Lymphoma
29%
Phase II Study
27%
Epidemiology
27%
Newly Diagnosed
26%
Minimal Residual Disease
25%
Prognostic Factors
25%
Angioimmunoblastic T-cell Lymphoma
25%
United States
24%
Older Patients
24%
Complete Response
24%
Chemotherapy
24%
Hodgkin Lymphoma
23%
Risk Factors
23%
Hematological Malignancies
23%
5-year Survival
23%
Overall Response Rate
21%
Brentuximab Vedotin
21%
Primary Central Nervous System Lymphoma (PCNSL)
21%
Multiple Myeloma
20%
Central Nervous System Relapse
20%
Hematopoietic Cell Transplantation
18%
High-dose Chemotherapy
18%
Myelodysplastic Syndrome
18%
High Risk
17%
Lymphoma Subtype
17%
Disease Progression
17%
MD Anderson Cancer Center
17%
Poor Outcome
16%
Chimeric Antigen Receptor T Cells (CAR-T)
15%
R-CHOP
15%
Cyclophosphamide
15%
Clinical Trials
15%
Medicine and Dentistry
Overall Survival
100%
Diseases
76%
Diffuse Large B-Cell Lymphoma
69%
Follicular Lymphoma
65%
Peripheral T-Cell Lymphoma
53%
Non-Hodgkin Lymphoma
46%
Malignant Neoplasm
44%
Mantle Cell Lymphoma
43%
MALT Lymphoma
43%
Central Nervous System
42%
Radiation Therapy
41%
Rituximab
40%
Progression Free Survival
37%
Hematologic Malignancy
34%
Adult T-Cell Leukemia/Lymphoma
31%
Hodgkin's Lymphoma
29%
Cohort Effect
28%
Chimeric Antigen Receptor T-Cell Immunotherapy
28%
Autologous Stem Cell Transplantation
28%
Multiple Myeloma
25%
Angioimmunoblastic T-Cell Lymphoma
24%
Prognostic Factor
23%
Primary Central Nervous System Lymphoma
22%
Anaplastic Large Cell Lymphoma
21%
T-Cell Lymphoma
21%
Cell Transplantation
21%
Hematopoietic Cell
21%
Hematopoietic Stem Cell Transplantation
21%
Cancer
20%
Disease Exacerbation
19%
Allogeneic Hematopoietic Stem Cell Transplantation
18%
High Dose Chemotherapy
18%
Multivariate Analysis
18%
Cumulative Incidence
17%
Methotrexate
17%
Brentuximab Vedotin
17%
Survival Rate
16%
B-Cell Lymphoma
16%
Hazard Ratio
16%
Cancer Registry
15%
Systemic Therapy
15%
B Cell
15%
Myeloma
14%
Infection
14%
Cytarabine
14%
T Cell
14%
Light Chain
13%
Elderly Patient
13%
positron emission tomographic scan
13%
Cohort Analysis
13%
Pharmacology, Toxicology and Pharmaceutical Science
Diseases
78%
Rituximab
70%
Overall Survival
62%
Diffuse Large B Cell Lymphoma
47%
Chemotherapy
41%
Progression Free Survival
34%
Hairy Cell Leukemia
33%
Malignant Neoplasm
31%
Follicular Lymphoma
27%
Hematologic Malignancy
27%
T Cell Leukemia
27%
Remission
26%
Brentuximab Vedotin
24%
Vincristine
22%
Minimal Residual Disease
21%
Disease Exacerbation
20%
Cladribine
20%
Mantle Cell Lymphoma
20%
Prednisone
18%
Anaplastic Large Cell Lymphoma
17%
Methotrexate
17%
Cyclophosphamide
15%
Cytarabine
15%
Ibrutinib
15%
Peripheral T Cell Lymphoma
15%
Phase II Trials
15%
Chimeric Antigen Receptor
14%
Chronic Myeloid Leukemia
13%
Nonhodgkin Lymphoma
13%
T Cell Lymphoma
13%
Infection
13%
Thrombocytopenia
12%
Clinical Trial
12%
Failure Free Survival
12%
Doxorubicin
12%
Myelodysplastic Syndrome
11%
Acute Myeloid Leukemia
11%
Anemia
10%
Human T-Lymphotropic Virus 1
9%
Survival Rate
8%
Drug Development
8%
Myeloma
8%
Neutropenia
7%
Vital Statistic
7%
Angioimmunoblastic T Cell Lymphoma
7%
Hodgkin Disease
7%
Lenalidomide
7%
Lymphocytopenia
7%
Cohort Study
7%
Monotherapy
6%